BlueHQ: The colorectal cancer patient support hub
Take control of your path with colorectal cancer at BlueHQ, a free support service for patients and caregivers powered by the Colorectal Cancer Alliance.
BlueHQ is support magnified
BlueHQ is your digital hub with personalized resources, tools, and communities. You can:
- Explore personalized resources
- Connect with your community
- Track treatments and office visits
- Access support from the Alliance
BlueHQ has the information I need without searching. I can also connect with the Alliance’s support team and other patients like me.
Knowledge and tools curated for you
The path with colorectal cancer is different for every patient and caregiver. BlueHQ suggests helpful tools and resources that align with your story. Get the information that matters.
Connect with others who get it
BlueHQ connects you to thousands of allies with similar experiences. In this community, you can skip the basics and get to what matters — how to cope with colorectal cancer.
Keep track of important details
Store notes from your journey — including doctor visits, counseling sessions, and more — safely and securely. Or use BlueHQ as a journal. You can search your notes later.
Improve your journey with BlueHQ
Stay in the know about CRC resources and news, keep track of personalized medical information, and connect with a community of allies.
More Alliance communities
Get connectedTop resources
Volunteer spotlight: Kelly Sanders
In this Q&A, get to know Kelly Sanders, a passionate and dedicated Colorectal Cancer Alliance volunteer from Allentown, Pennsylvania, and consider becoming one yourself.
Healthcare and the 2024 election
We strongly encourage voters to contact the candidates in both parties and request information on their plans to improve access to healthcare and lower costs.
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.